Cellution Biologics announced its official entry into the ocular market with the debut of OptiCover, a next-generation amniotic graft designed for ocular surface protection.

The company said OptiCover is intended for use as a protective covering for the ocular surface and is designed to help physicians manage a range of ocular surface conditions, including symptoms associated with dry eye disease. According to Cellution, OptiCover is the first shelf-stable, lyophilized amniotic graft containing HC-HA/PTX3 while retaining native components of amniotic tissue. The company said these biologic components are integral to the tissue’s inherent structure and contribute to its protective properties.

By preserving these components in a shelf-stable format, the graft aims to offer clinicians the biologic advantages of amniotic tissue alongside greater convenience and accessibility in everyday practice settings.

“Ocular surface disease and dry eye remain among the most common and frustrating conditions physicians manage every day,” said Shiva Arjunon, president of Cellution Biologics. “OptiCover was developed to address the real-world challenges clinicians face with existing solutions: awkward handling, storage limitations, and inconsistent results. Our goal was to deliver a graft that combines advanced biologic function with practical usability in the clinic."

The company emphasized that OptiCover was engineered with handling characteristics intended to simplify in-office application. The graft’s structure allows physicians to place and position the membrane more easily without creasing, potentially improving procedural efficiency and reducing the risk of abrasions during placement.

Unlike some competing products that require specialized frozen storage conditions ranging from -80°C to 4°C, OptiCover is shelf-stable, allowing practices to store the graft at room temperature and maintain immediate access when treatment is needed, according to Cellution. The company said this may help eliminate logistical barriers associated with biologic storage and support faster clinical decision-making and treatment delivery.

Cellution Biologics said its ocular product expansion is supported by decades of experience in regenerative biologics and access to an American Association of Tissue Banks (AATB)-accredited tissue bank, enabling the company to provide high-quality amniotic graft products across multiple medical specialties. The company also confirmed that additional ocular products and regenerative technologies are currently in development as part of its broader strategy to expand within ophthalmology and ocular surface care.